CancerSeq™ Paraffin Tissue Samples
Extensively validated tumor tissues
CancerSeq™ formalin fixed paraffin embedded (FFPE) tissues are tumor tissues that have been prescreened extensively for single nucleotide polymorphisms (SNPs), insertions & deletions (indels), and copy number variations (CNVs). Targeted Next Generation Sequencing (NGS), using cancer gene panels, was performed to identify mutations and mutational hotspots. These tissues are ideal for verification, genotyping, or identification of new mutations.
See all CancerSeq Paraffin Tissue samples
Features
- Deep sequencing by NGS with high coverage
- FFPE curls or slides available (inquire for blocks)
- Documentation of the tissue donor’s clinical histories is available
- Information regarding tumor type is available
- Complete NGS sequencing data available (including chromosomal position, variant type (SNP or indel), alternate allele variations, quality score, depth of coverage, allele type, transcript ID and more)
Applications
- Validation of cancer marker mutation related drug candidates
- Controls or verification for genotyping
- Companion diagnostic assay development
- Suitable for both IHC and in-situ hybridization assays
- Cellular localization of tissue specific mRNA and protein expression
- Isolation of DNA and RNA with specific mutation profiles
How are CancerSeq™ Tissue Generated?
To generate our CancerSeq™ line of tissues, genomic DNA was extracted from the FFPE tissues and validated by targeted NGS using Illumini TruSeq Cancer Panel for CancerSeq™, or ArcherDx VariantPlex for CancerSeq™ Plus tissue, or Thermo Fisher Ion AmpliSeq panel for CancerSeq™ AMS.
• Offers greater sequencing depth by focusing on a panel of genes of clinical relevance
• Allows identification of low frequency variants with high confidence
• Useful for patient stratification and the development of targeted therapeutics
• Powerful for profiling FFPE samples
• Can pick out mutations present in a fraction of malignant cells generating valuable information for therapeutic targets and immunotherapy biomarkers
CancerSeq™ Product Line
CancerSeq™
- Illumina TruSeq Cancer Panel
- 48 genes are targeted with 212 amplicons
- Detect somatic mutations in mutational hotspots
- Sensitive mutation detection within genes such as BRAF and KRAS
- Bead based sample normalization
- Blocks and slides available for lung, skin melanoma, breast, colon tumors (inquire for curls)
CancerSeq™ Plus
- ArcherDx VariantPlex platform
- Expanded 67 cancer gene panel
- Anchored Multiplex PCR (AMP) chemistry
- Greater target recovery from short fragments
- Detects gene fusions, SNPs, indels and CNVs
- Breast, Lung, Stomach, Thyroid tumours
- Each lot is supplied as 5 curls/scrolls per vial
CancerSeq™ AMS
- Thermo Fisher Ion AmpliSeq panel
- non-small-cell lung carcinoma (NSCLC) tumor tissues
- 35 cancer genes
Real Tumor Tissue vs. Cancer Cell Lines
Real tumor tissues are far more representative of real clinical disease than genetically engineered tumor cell lines. Cancer cell lines or genetically altered cell lines have been used widely for in vitro tumor models, but these possess only a small proportion of the genetic variances seen in tumor tissues; real tumors generally carry multiple mutations instead of just one or two. Numerous studies have pointed out the striking genetic differences between cell lines and tumor samples by comparing microarrays, copy number changes, mutations, and mRNA expression profiles.
